SHARE            


Can an Apple Watch®*, by itself, provide adequate warning that you’re experiencing heart issues such as atrial fibrillation (AFib)? According to the results of one study, probably not.



Alan Cheng discusses how insertable heart monitors compare with wearable devices in advancing cardiac rhythm management and long-term patient monitoring.

“Wearables allow patients to capture more real-time heart health data than ever before, but this study shows medical-grade technology is still necessary to provide doctors with an accurate and reliable way to detect and manage cardiac conditions like AFib.”


–Dr. Alan Cheng, chief medical officer of the Cardiac Rhythm Management business at Medtronic 



AFib is an irregular and potentially dangerous heart rhythm that’s becoming increasingly common in the United States. It’s a serious, chronic, and progressive heart disease, and it’s estimated that by 2030, more than 12 million Americans will have AFib.1 Wearable devices such as smart watches that can detect AFib have become increasingly popular.

But the first-of-its-kind, app-based DEFINE AFib clinical study found that the Medtronic Reveal LINQ™ insertable cardiac monitor (ICM), a small medical-grade heart monitor implanted under the skin, detected more episodes of AFib than the wearable did.

In the study, 40% of AFib episodes happened while the Apple Watch®* wasn’t being worn.2  AFib episodes can happen at night when wearables are often removed to recharge. The ICM, on the other hand, monitors heart activity 24 hours a day, seven days a week, for years at a time.  

In addition, the study found that when the Apple Watch®* was being worn, its irregular rhythm notification feature detected only 26% of the AFib episodes found by the ICMs.3

Does this mean you should ditch your wearable?

Absolutely not.

If a wearable detects an AFib episode, the individual wearing it likely had an AFib event, noted Jonathan P. Piccini, M.D., clinical cardiac electrophysiologist and professor of medicine and population health at Duke University Hospital and the Duke Clinical Research Institute, and chair of the DEFINE AFib clinical study steering committee.

But the watch may not catch every episode.  

“Smart watches are a great tool to give you a sense of your overall health status,” added Dr. Cheng. “Medical-grade devices with continuous monitoring capabilities are more appropriate for screening for and especially helping manage chronic conditions like AFib.” 



Jonathan Paul Piccini shares clinical insight on heart monitoring technologies, drawing on his expertise in cardiac electrophysiology and population health research.

“For doctors, the primary take-home bedside message is that consumer wearables can have limitations. So it’s really important to validate that with continuous monitoring technology to make sure we have the right answer.”


–Dr. Jonathan Piccini, clinical cardiac electrophysiologist and professor of medicine and population health at Duke University Hospital



 

© 2026 Medtronic. Medtronic, Medtronic logo, and Engineering the Extraordinary are trademarks of Medtronic.  

®* and ™* Third-party brands are trademarks of their respective owners. Apple Watch® is a registered trademark of Apple, Inc. All other brands are trademarks of a Medtronic company.  

Important safety information about the LINQ family of ICMs: https://www.medtronic.com/en-us/l/patients/treatmentstherapies/insertable-heart-monitors/gettingmonitor/important-safety-information.html